Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$7.72
+3.1%
$7.73
$6.85
$19.66
$445.42M-0.08348,309 shs571,374 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$14.40
-1.2%
$13.18
$4.81
$27.50
$483.75MN/A324,482 shs215,057 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$3.36
-0.6%
$3.74
$1.14
$7.11
$108.46M2.34269,515 shs96,135 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$7.44
-1.6%
$5.78
$1.87
$11.40
$609.08M-0.041.09 million shs1.04 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+3.07%-2.65%-2.77%-11.67%-58.29%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-1.17%+0.63%+14.83%+21.42%+1,439,999,900.00%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-0.59%-2.89%-7.44%+55.84%-42.95%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-1.59%+7.98%+29.39%+110.17%+2.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
2.6382 of 5 stars
3.52.00.00.03.01.70.6
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.3149 of 5 stars
3.50.00.00.02.21.70.6
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.2227 of 5 stars
3.63.00.00.02.40.80.0
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.9392 of 5 stars
3.31.00.04.13.13.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$26.80247.15% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.63161.28% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.14
Buy$15.50361.31% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63110.01% Upside

Current Analyst Ratings Breakdown

Latest SKYE, MBX, TERN, and CGEM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$24.00
8/18/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$35.00 ➝ $28.00
8/15/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/14/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
8/5/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/16/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
6/24/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
6/11/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$8.33 per shareN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$1.41 per shareN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$3.49 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A-$4.54N/AN/AN/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$26.57M-$1.06N/AN/AN/AN/A-76.03%-69.20%N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)

Latest SKYE, MBX, TERN, and CGEM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.83-$1.07-$0.24-$1.07N/AN/A
8/7/2025Q2 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.34-$0.44-$0.10-$0.44N/AN/A
8/5/2025Q2 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.28-$0.26+$0.02-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
9.83
9.83
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
6.09
6.09
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
24.70
24.70

Institutional Ownership

CompanyInstitutional Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
6.07%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.07 million55.49 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.59 millionN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.99 million30.06 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.51 million86.20 millionNot Optionable

Recent News About These Companies

Weight-Loss Wasteland: 5 Obesity Assets That Failed
Terns (TERN) Q2 Net Loss Narrows 16%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$7.72 +0.23 (+3.07%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$7.72 0.00 (-0.06%)
As of 09/3/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$14.40 -0.17 (-1.17%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$14.40 -0.01 (-0.03%)
As of 09/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$3.36 -0.02 (-0.59%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$3.46 +0.10 (+2.83%)
As of 09/3/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$7.44 -0.12 (-1.59%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$7.45 +0.01 (+0.08%)
As of 09/3/2025 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.